文献速递物质与行为成瘾

基准乘法法估计美国物质使用障碍患病率

Estimating the Prevalence of Substance Use Disorders in the US Using the Benchmark Multiplier Method.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

本研究采用基准乘法法,基于2018-2019年T-MSIS医疗补助数据(基准)和NSDUH全国调查数据(乘数),估计美国12岁及以上人群酒精、大麻、阿片类和兴奋剂使用障碍的患病率。结果显示基准乘法法估计值均高于NSDUH估计值,提示美国物质使用障碍负担可能被低估。

要点

  • 基准乘法法估计的酒精使用障碍患病率为20.27%,远高于NSDUH的5.34%。
  • 大麻、阿片类和兴奋剂使用障碍的基准乘法法估计值也均高于NSDUH估计值。
  • 敏感性分析显示,在广泛的乘数值范围内,两种方法的估计差异持续存在。

核心结论

  • 基准乘法法估计的美国物质使用障碍患病率高于NSDUH估计值,提示这些疾病的负担可能更大。

研究设计与样本

  • 采用基准乘法法,基于2018和2019年T-MSIS医疗补助受益者行政数据(基准)和NSDUH全国代表性横断面调查数据(乘数)进行估计。
  • 研究对象为12岁及以上医疗补助受益者(过去一年因酒精、大麻、阿片类或兴奋剂使用障碍接受治疗服务)和NSDUH参与者(符合12个月DSM-IV物质使用障碍诊断)。

主要发现

  • 2018-2019年合并样本中,基准乘法法估计的酒精使用障碍患病率为20.27%(95%CI 17.04-24.71),NSDUH估计为5.34%(95%CI 5.10-5.58)。
  • 大麻使用障碍的基准乘法法估计为7.57%(95%CI 5.96-9.93),NSDUH估计为1.68%(95%CI 1.59-1.79)。
  • 阿片类使用障碍的基准乘法法估计为3.46%(95%CI 2.97-4.12),NSDUH估计为0.68%(95%CI 0.60-0.78)。
  • 兴奋剂使用障碍的基准乘法法估计为1.91%(95%CI 1.63-2.30),NSDUH估计为0.85%(95%CI 0.75-0.96)。
  • 敏感性分析显示,在广泛的乘数值范围内,基准乘法法与NSDUH估计的差异持续存在。

关键数值与推荐

  • 基准乘法法估计值在2018和2019年以及合并样本中均高于NSDUH估计值,覆盖所有物质类型。

临床怎么用

  • 临床医生应意识到基于一般人群调查的患病率可能低估物质使用障碍的实际负担,尤其在医疗补助受益人群中。
  • 在筛查和评估物质使用障碍时,应考虑被调查遗漏的高风险群体(如无家可归者、机构化人群)及低报问题。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prevalence estimates of substance use disorders in the US rely on general population surveys. However, major population groups, such as homeless individuals and institutionalized individuals, are not captured by these surveys, and participants may underreport substance use. OBJECTIVE: To estimate the prevalence of substance use disorders in the US. DESIGN, SETTING, AND PARTICIPANTS: The benchmark multiplier method was used to estimate the prevalence of alcohol, cannabis, opioid, and stimulant use disorders based on data from the Transformed Medicaid Statistical Information System (T-MSIS) (the benchmark) and the National Survey on Drug Use and Health (NSDUH) (the multiplier) for 2018 and 2019. T-MSIS collects administrative data on Medicaid beneficiaries 12 years and older with full or comprehensive benefits. NSDUH is a nationally representative annual cross-sectional survey of people 12 years and older. Data were analyzed from February to June 2022. MAIN OUTCOMES AND MEASURES: Prevalence of substance use disorders was estimated using the benchmark multiplier method based on T-MSIS and NSDUH data. Confidence intervals for the multiplier method estimates were computed using Monte Carlo simulations. Sensitivity of prevalence estimates to variations in multiplier values was assessed. RESULTS: This study included Medicaid beneficiaries 12 years and older accessing treatment services in the past year with diagnoses of alcohol (n = 1 017 308 in 2018; n = 1 041 357 in 2019), cannabis (n = 643 737; n = 644 780), opioid (n = 1 406 455; n = 1 575 219), and stimulant (n = 610 858; n = 657 305) use disorders and NSDUH participants with 12-month DSM-IV alcohol (n = 3390 in 2018; n = 3363 in 2019), cannabis (n = 1426; n = 1604), opioid (n = 448; n = 369), and stimulant (n = 545; n = 559) use disorders. The benchmark multiplier prevalence estimates were higher than NSDUH estimates for every type of substance use disorder in both years and in the combined 2018 to 2019 sample: 20.27% (95% CI, 17.04-24.71) vs 5.34% (95% CI, 5.10-5.58), respectively, for alcohol; 7.57% (95% CI, 5.96-9.93) vs 1.68% (95% CI, 1.59-1.79) for cannabis; 3.46% (95% CI, 2.97-4.12) vs 0.68% (0.60-0.78) for opioid; and 1.91% (95% CI, 1.63-2.30) vs 0.85% (95% CI, 0.75-0.96) for stimulant use disorders. In sensitivity analyses, the differences between the benchmark multiplier method and NSDUH estimates persisted over a wide range of potential multiplier values. CONCLUSIONS AND RELEVANCE: The findings in this study reflect a higher national prevalence of substance use disorders than that represented by NSDUH estimates, suggesting a greater burden of these conditions in the US.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Mojtabai R. Estimating the Prevalence of Substance Use Disorders in the US Using the Benchmark Multiplier Method. JAMA Psychiatry. 2022. PMID: 36129721. doi:10.1001/jamapsychiatry.2022.2756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。